The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics may also be considered.

Patients with palmoplantar pustulosis have a high disease burden, with younger patients and those with nail involvement having worse quality of life.

Adults with acne were found to be significantly more likely to have an eating disorder, even accounting for comorbid mental health disorders.

The Food and Drug Administration has granted Fast Track designation to bempikibart for the treatment of alopecia areata.

The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

Since 1992, research from the ongoing Women's Health Initiative prevented an estimated 126,000 breast cancer cases and produced more than 2400 scientific publications.

Patients with psoriatic arthritis waited longer for diagnosis and were less likely to be prescribed disease-modifying antirheumatic drugs.

Additional research is needed on the efficacy, safety, and appropriate uses of various cosmeceuticals for patients’ skin care concerns.

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.